Chronic Myelomonocytic Leukemia (CMML) Clinical Trials

Find Chronic Myelomonocytic Leukemia (CMML) Clinical Trials Near You

Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) who have an intermediate-2 or high-risk prognosis. The main goal is to evaluate 1 year RFS and OS. Other goals include assessing engraftment, overall survival, transplant-related complications, and side effects. A total of 31 participants will be enrolled.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years, any sex/gender.

• Confirmed diagnosis of chronic myelomonocytic leukemia (CMML) according to the 2022 WHO classification.

• Intermediate-2 or high-risk CMML based on CPSS or CPSS-mol score, and planned to receive allo-HSCT.

• Has a suitable hematopoietic stem cell donor:

• For haploidentical donor: at least 5/10 HLA match at HLA-A, -B, -C, -DQB1, and -DRB1.

• For unrelated donor: at least 9/10 HLA match at the same five loci.

• For matched sibling donor: 10/10 HLA match at the same five loci.

• Hematopoietic cell transplantation comorbidity index (HCT-CI) ≤ 2, with generally good health and no significant organ abnormalities or major comorbidities.

• Adequate organ function as defined below:

• Left ventricular ejection fraction (LVEF) ≥ 50%, and no uncontrolled tachycardia or bradycardia-tachycardia syndrome.

• Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT ≤ 2 × ULN; AST ≤ 2 × ULN.

• Serum creatinine ≤ 1.5 × ULN.

• Baseline oxygen saturation \> 92%.

• Pulmonary function: DLCO (corrected for hemoglobin) ≥ 40%, FEV1 ≥ 50%.

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

• Agrees not to participate in any other interventional study during the treatment period.

• Willing and able to provide written informed consent, understand the nature, purpose, and procedures of the study, and voluntarily comply with study requirements.

Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Yuqian Sun, MD
sunyuqian83@hotmail.com
+86 13717833825
Backup
Xueyi Luo, MD
lll_xxx_yyy@126.com
+86 13811936698
Time Frame
Start Date: 2026-02-13
Estimated Completion Date: 2028-05
Participants
Target number of participants: 31
Treatments
Experimental: Single Arm: Thiotepa + Busulfan + Fludarabine ± ATG
Patients with intermediate-2 or high-risk chronic myelomonocytic leukemia (CMML) per CPSS/CPSS-mol criteria, who are scheduled to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a thiotepa-containing conditioning regimen.
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov